Gonadorelin: real GnRH with a proven pump role — and an unproven TRT-adjunct pitch

Gonadorelin is one of the few molecules in the men’s-clinic peptide world that is not a gray-market invention at all: it is synthetic gonadotropin-releasing hormone (GnRH), the exact ten-amino-acid hormone the hypothalamus uses to run the entire reproductive axis. It has a real pharmacology, a real diagnostic history, and a genuine — if narrow — therapeutic role. What it does not have is good evidence for the way it is most often sold today: as a convenient, cheap stand-in for hCG to keep the testicles working during testosterone therapy. The gap between those two facts is almost entirely a problem of rhythm, and that is the thread of this piece.

What it is: the body’s own master signal, made synthetic

At the very top of the hormonal cascade that controls fertility and testosterone sits GnRH, released by the hypothalamus. GnRH travels a short distance to the pituitary, where it triggers the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH drives the testes’ Leydig cells to make testosterone; FSH supports the Sertoli cells that run spermatogenesis. Gonadorelin is simply that native GnRH decapeptide reproduced as a drug. So unlike kisspeptin — which sits one step further upstream and tells the GnRH neurons themselves to fire — gonadorelin is the GnRH signal, acting directly on the pituitary.

The detail that governs everything: pulse, not flood

Here is the single most important fact about GnRH, and the one the marketing quietly ignores. The hypothalamus does not pour GnRH out continuously; it releases it in discrete pulses, roughly once every ninety minutes. That rhythm is not decoration — it is the message. In the landmark experiments that defined the field, delivering GnRH to the pituitary in intermittent pulses sustained normal LH and FSH secretion, whereas delivering the same hormone continuously shut the axis down: the pituitary receptors desensitised and gonadotropin output collapsed.^[1] This is why the long-acting GnRH agonists used in prostate cancer and precocious puberty work by paradoxically suppressing the axis — they flood the receptor and turn it off. The lesson is blunt: with GnRH, the waveform is the medicine. Get the rhythm wrong and you get the opposite of what you intended.

Where the evidence is genuinely strong: pulsatile-pump therapy and fertility

When GnRH is delivered the way the body delivers it — in small pulses from a portable infusion pump every couple of hours — it is a legitimate, evidence-backed treatment. In men with hypogonadotropic hypogonadism (a hypothalamic GnRH deficiency, the form seen in Kallmann syndrome and related conditions), long-term pulsatile administration of low-dose GnRH was shown decades ago to induce puberty, raise testosterone into the normal range, and initiate spermatogenesis.^[2] Modern data reinforce it: in men with congenital hypogonadotropic hypogonadism, pulsatile GnRH therapy was associated with earlier spermatogenesis than combined gonadotropin (hCG plus hMG) therapy, because it restores the whole upstream axis rather than replacing the downstream hormones.^[3]European expert consensus lists pulsatile GnRH alongside gonadotropins as a standard option for inducing fertility in these patients.^[4] This is the real clinical home of gonadorelin — and notice that every bit of that evidence depends on the pulsatile pump, not on a syringe.

Its other legitimate job: the diagnostic GnRH stimulation test

Gonadorelin also has a long history as a diagnostic agent. In the GnRH stimulation test, a single dose is injected and LH and FSH are measured before and after, probing whether the pituitary can still respond to the signal — useful in working up delayed puberty and in distinguishing hypothalamic from pituitary causes of reproductive failure. Contemporary reviews of how clinicians assess the hypothalamic-pituitary-gonadal axis still describe GnRH-based dynamic testing among the tools for characterising these disorders, while noting its interpretive limits.^[5] This is the use the original branded product (Factrel) was approved for — a diagnostic, given once, not a chronic therapy.^[6] It is a real, narrow, well-defined role, and worth separating cleanly from the marketed one that follows.

The modern men’s-clinic use — and why the evidence does not follow it there

The reason gonadorelin is suddenly everywhere is none of the above. Telehealth and anti-aging clinics prescribe it as an alternative to hCG for men on testosterone replacement therapy (TRT). Exogenous testosterone suppresses LH and FSH, which causes the testes to shrink and shut down sperm production; the standard fix has been hCG, which mimics LH and keeps the testes active. Gonadorelin is pitched as a cheaper, more “natural” substitute — stimulate the pituitary, let the man’s own LH do the work. Mechanistically the story is tidy. The problem is the rhythm again. The clinical evidence that works uses a pump delivering pulses every ninety minutes; the clinic protocol is a subcutaneous bolus injection once or twice a day. That is the wrong waveform on the very axis whose defining feature is that continuous or poorly-timed exposure desensitises it. Native GnRH also has an extremely short half-life — minutes — so a single daily injection produces a brief, sharp spike and then nothing, bearing little resemblance to either the natural pulse train or the steady pump regimen.

Crucially, there are no adequately powered randomized trials showing that bolus gonadorelin preserves testicular volume, intratesticular testosterone, or fertility in men on TRT — let alone that it does so as well as hCG, the comparison that actually matters. The pulsatile-pump and diagnostic evidence above does not transfer to a once-daily shot; using it as if it does is a category error. This is the same pattern we flag for enclomiphene, another HPG-axis drug repurposed off-label for testosterone goals: a coherent mechanism and a real evidence base for one use do not automatically validate a different protocol, dose, and population.

How it differs from kisspeptin and enclomiphene

It is worth being precise about where gonadorelin sits among the reproductive-axis tools, because they are routinely conflated. Kisspeptin acts above GnRH, on the neurons that release it — it is the upstream trigger. Enclomiphene works by a different route entirely: it is an oral SERM that blocks estrogen’s negative feedback at the hypothalamus, so the body raises its own GnRH, LH, and FSH. Gonadorelin is the GnRH molecule itself, given directly. That distinction matters for the TRT-adjunct debate: enclomiphene and clomiphene have actual randomized human data behind their effect on the axis, whereas bolus gonadorelin’s adjunct use rests on extrapolation from a differently-delivered, differently-purposed body of evidence.

The supply and approval reality

The branded diagnostic forms of gonadorelin have largely been discontinued in the United States, so the product men actually receive for TRT support comes overwhelmingly from compounding pharmacies, prescribed off-label. That places it in the same structural position as the rest of the injectable-peptide market: there is no FDA-approved, quality-controlled product on the U.S. market for the chronic male use it is sold for, and compounded supply means the identity, dose accuracy, and sterility of any given vial are not independently guaranteed. Those quality unknowns sit on top of the efficacy question, not instead of it.

The honest bottom line

Gonadorelin deserves real respect for what it is: authentic synthetic GnRH, with a legitimate diagnostic role and a genuinely evidence-backed therapeutic one — pulsatile-pump treatment of hypogonadotropic hypogonadism, where it restores the whole axis and can drive fertility. But that evidence is inseparable from the pulsatile delivery that defines how GnRH works. The popular men’s-clinic use — a once-daily bolus injection as a cheaper hCG substitute on TRT — borrows credibility from the pump data while ignoring the one variable, rhythm, that the pump data exist to prove. The mechanism is plausible; the head-to-head human evidence for the bolus protocol is missing. Respect the hormone and its proven, narrow uses — and treat the TRT-adjunct pitch as the unvalidated extrapolation it currently is.